PSA

What to Expect in Veganuary 2024: New Menu Items and Specials Launch Nationwide

Retrieved on: 
Thursday, December 28, 2023

Veganuary works with restaurants, retailers, and brands nationwide to create specials for the enormous number of people who sign up to take the month-long challenge each year.

Key Points: 
  • Veganuary works with restaurants, retailers, and brands nationwide to create specials for the enormous number of people who sign up to take the month-long challenge each year.
  • Plus, numerous pizza chains will launch special menu items, including Mellow Mushroom, &pizza, and Sizzle Pie.
  • All the new vegan menu items, products, and recipes promoted during Veganuary allow for people to eat more plants without giving up the foods they know and love,” says Sandra Hungate, US Director at Veganuary.
  • Veganuary is supported worldwide by environmentalists, athletes, and celebrities, including Joaquin Phoenix, DeAndre Jordan, Richa Moorjani, and more.

Cipher Mining Announces the Closing of its Acquisition of Black Pearl

Retrieved on: 
Friday, December 8, 2023

Pursuant to the terms of the PSA, the Purchase Price under the PSA is paid by delivery of an aggregate of 2,397,424 shares of the Company’s common stock.

Key Points: 
  • Pursuant to the terms of the PSA, the Purchase Price under the PSA is paid by delivery of an aggregate of 2,397,424 shares of the Company’s common stock.
  • “We are thrilled to have closed on acquiring our new Texas-based, ERCOT-approved site, called Black Pearl,” said Tyler Page, Cipher’s CEO.
  • “With interconnection up to 300 MW, we expect Black Pearl to become the largest of our sites.
  • We’re excited to get started on building Black Pearl, and expect to start deploying mining rigs at the site in a little more than a year.”

Selectis Health Enters Agreements to Sell Four Skilled Nursing Facilities in Georgia

Retrieved on: 
Tuesday, December 5, 2023

Greenwood Village, Colorado, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Selectis Health, Inc. (OTC: GBCS) ("Selectis" or the "Company") announced that several wholly owned affiliates (the “Affiliates”)1 have entered into agreements to sell the Company’s four owned and operated skilled nursing facilities in Georgia. The agreements provide for the sale of the Company’s Warrenton Healthcare & Rehabilitation, Eastman Healthcare & Rehabilitation, Glen Eagle Nursing and Rehabilitation, and Providence of Sparta Healthcare & Rehabilitation facilities, for an aggregate consideration of $31 million.

Key Points: 
  • To close the transaction, the Purchaser must obtain the facilities’ required operating licenses from the Georgia Department of Community Health, along with other necessary federal and state regulatory certifications, operational licenses, and permits.
  • The Affiliates and Purchaser must also satisfy all due diligence provisions and requirements set forth in the PSA.
  • Pursuant to the agreements, the facilities will be sold for an aggregate consideration of $31 million.
  • Adam Desmond, interim CEO of Selectis Health, commented: “The attractive valuation of our Georgia facilities is a testament to the success of our facility-level financing and operational improvement initiatives.

Lotus Resources Ltd to Present at the Clean Energy and Precious Metals Virtual Investor Conference December 4th.

Retrieved on: 
Friday, December 1, 2023

PERTH, Australia, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Lotus Resources (ASX:LOT; OTCQB:LTSRF), based in Perth, Australia, focused on uranium development projects, today announced that Keith Bowes, Managing Director, will present live at the Clean Energy and Precious Metals Virtual Investor Conference, hosted by VirtualInvestorConferences.com, on December 4th.

Key Points: 
  • PERTH, Australia, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Lotus Resources (ASX:LOT; OTCQB:LTSRF), based in Perth, Australia, focused on uranium development projects, today announced that Keith Bowes, Managing Director, will present live at the Clean Energy and Precious Metals Virtual Investor Conference, hosted by VirtualInvestorConferences.com, on December 4th.
  • This will be a live, interactive online event where investors are invited to ask the company questions in real-time.
  • It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates.
  • Completion of the Merger with A-Cap Energy and the inclusion of the Letlhakane Project into Lotus’ portfolio of uranium assets.

Ambrx Provides Update On APEX-01, an On-Going Phase 1 / 2 Dose Escalation Study Evaluating ARX517, a Proprietary PSMA-Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer

Retrieved on: 
Tuesday, November 28, 2023

SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., or Ambrx (NASDAQ: AMAM), today announced a clinical update regarding its proprietary anti-PSMA antibody drug conjugate (ADC) ARX517 in the ongoing APEX-01 Phase 1 / 2 dose escalation and dose expansion clinical trial in metastatic castration-resistant prostate cancer (mCRPC).

Key Points: 
  • Following the completion of the 21-day DLT observation period from APEX-01 dose escalation Cohort 9 (3.4 mg/kg), no DLTs or SAEs were observed.
  • A PSA decrease was not reported in the third patient because the patient had non-PSA secreting mCRPC.
  • On Monday November 27, the safety monitoring committee (SMC) voted to dose escalate to 4.5 mg/kg (Cohort 10) as well as expand patients at the 3.4 mg/kg dose (Cohort 9).
  • We believe this is a direct result of the stability of conjugation supported by PK data presented at ESMO last month.

Metastatic Castration-Resistant Prostate Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 7.5% During the Study Period (2019-2032), Estimates DelveInsight

Retrieved on: 
Wednesday, December 20, 2023

LAS VEGAS, Dec. 20, 2023 /PRNewswire/ -- DelveInsight's Metastatic Castration-Resistant Prostate Cancer Market Insights report includes a comprehensive understanding of current treatment practices, mCRPC emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key Points: 
  • As per DelveInsight analysis, the total metastatic castration-resistant prostate cancer market size in the 7MM was estimated to be nearly USD 6.4 billion in 2022, which is expected to show positive growth by 2032.
  • As per DelveInsight estimates, in 2022, total diagnosed prevalent cases of mCRPC were around 127K in the 7MM.
  • However, mCRPC remains a lethal diagnosis and more effective therapeutic approaches against mCRPC are necessary to improve clinical outcomes further.
  • The estimated five-year survival rate for men with metastatic prostate cancer is approximately 30%, in stark contrast to the 100% survival rate for those with localized prostate cancer.

Metastatic Castration-Resistant Prostate Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 7.5% During the Study Period (2019-2032), Estimates DelveInsight

Retrieved on: 
Wednesday, December 20, 2023

LAS VEGAS, Dec. 20, 2023 /PRNewswire/ -- DelveInsight's Metastatic Castration-Resistant Prostate Cancer Market Insights report includes a comprehensive understanding of current treatment practices, mCRPC emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key Points: 
  • As per DelveInsight analysis, the total metastatic castration-resistant prostate cancer market size in the 7MM was estimated to be nearly USD 6.4 billion in 2022, which is expected to show positive growth by 2032.
  • As per DelveInsight estimates, in 2022, total diagnosed prevalent cases of mCRPC were around 127K in the 7MM.
  • However, mCRPC remains a lethal diagnosis and more effective therapeutic approaches against mCRPC are necessary to improve clinical outcomes further.
  • The estimated five-year survival rate for men with metastatic prostate cancer is approximately 30%, in stark contrast to the 100% survival rate for those with localized prostate cancer.

Eurotech publishes Everyware GreenEdge software in AWS Marketplace: a simple, innovative, and secure way to onboard to AWS IoT services

Retrieved on: 
Tuesday, December 19, 2023

AMARO, Italy, Dec. 19, 2023 /PRNewswire/ -- Eurotech, a provider of Edge Artificial Intelligence of Things (AIoT) technologies, is proud to introduce Everyware GreenEdge - a software solution designed to address typical challenges that occur during the onboarding and management of Edge Internet of Things (IoT) devices at scale. These challenges include time-consuming errors, security vulnerabilities, inconsistent data, and ultimately, unmanageable IoT devices with insecure credentials.

Key Points: 
  • With Everyware GreenEdge, customers can effortlessly enroll edge devices with just a few clicks and establish connection to Amazon Web Services (AWS), unlocking access to the full suite of AWS services, including AWS IoT Analytics.
  • More than a product, Everyware GreenEdge empowers our customers to achieve their digital ambitions with confidence and speed," Chawla concludes.
  • Everyware GreenEdge merges the functionality of AWS IoT Greengrass and Eurotech's Everyware Software Framework (ESF), and leverages capabilities of Eurotech's Everyware Cloud (EC) for remote device management.
  • In addition to its technical advantages, Everyware GreenEdge comes with a unified billing system for all software and services related costs in Amazon Marketplace.

Eurotech publishes Everyware GreenEdge software in AWS Marketplace: a simple, innovative, and secure way to onboard to AWS IoT services

Retrieved on: 
Tuesday, December 19, 2023

AMARO, Italy, Dec. 19, 2023 /PRNewswire/ -- Eurotech, a provider of Edge Artificial Intelligence of Things (AIoT) technologies, is proud to introduce Everyware GreenEdge - a software solution designed to address typical challenges that occur during the onboarding and management of Edge Internet of Things (IoT) devices at scale. These challenges include time-consuming errors, security vulnerabilities, inconsistent data, and ultimately, unmanageable IoT devices with insecure credentials.

Key Points: 
  • With Everyware GreenEdge, customers can effortlessly enroll edge devices with just a few clicks and establish connection to Amazon Web Services (AWS), unlocking access to the full suite of AWS services, including AWS IoT Analytics.
  • More than a product, Everyware GreenEdge empowers our customers to achieve their digital ambitions with confidence and speed," Chawla concludes.
  • Everyware GreenEdge merges the functionality of AWS IoT Greengrass and Eurotech's Everyware Software Framework (ESF), and leverages capabilities of Eurotech's Everyware Cloud (EC) for remote device management.
  • In addition to its technical advantages, Everyware GreenEdge comes with a unified billing system for all software and services related costs in Amazon Marketplace.

PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, November 14, 2023

The Company will provide a business update on its conference call and webcast at 8:00 AM EST today.

Key Points: 
  • The Company will provide a business update on its conference call and webcast at 8:00 AM EST today.
  • PDS Biotech anticipates initiation of VERSATILE-003 in Q1 2024.
  • PDS Biotech’s cash balance as of September 30, 2023 was approximately $54.3 million.
  • PDS Biotech believes that, with initiating the VERSATILE-003 Phase 3 clinical trial in the first quarter of 2024, its available cash resources will sustain operational and research and development endeavors into the third quarter of 2024.